Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer

Overview of attention for article published in Frontiers in oncology, September 2020

Altmetric Badge

Mentioned by

So far, Altmetric has seen 1 X post from an account with 792 followers.

Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer https://t.co/lWMIgtDdGK

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.